Literature DB >> 5309797

Altered immunoglobulin metabolism in systemic lupus erythematosus and heumatoid arthritis.

J Levy, E V Barnett, N S MacDonald, J R Klinenberg.   

Abstract

IgG and IgM metabolism was evaluated in 10 patients with systemic lupus erythematosus (SLE), 10 patients with rheumatoid arthritis (RA), and in seven normal volunteers. The biological half-lives of purified IgG and IgM, labeled with (131)I and (125)I, respectively, were determined by serial measurements of radioactivity in the blood and urine with a gamma well counter, and by serial counts of total body radioactivity in a total body counting chamber. The mean survival half-life for IgG in patients with SLE was 8.2 days as compared to an average of 18 days in normal controls. An average of 10.1% of total body IgG was catabolized daily compared to a mean of 3.9% in normal controls. Turnover of IgM in patients with SLE was, with very few exceptions, normal. In contrast, patients with rheumatoid arthritis revealed a milder abnormality of IgG metabolism, but markedly abnormal IgM catabolism with a mean half-life averaging 5.9 days as compared to 9.3 days in control subjects. An average of 14.2% of total body IgM was catabolized daily in patients with RA as compared to 8.1% in normal controls. Our data suggest that there are basic differences between patients with RA and SLE in the synthesis and catabolism of IgG and IgM not readily apparent from serum IgG and IgM concentration. Abnormal IgG and IgM metabolism may be related to underlying immunological mechanisms in these diseases. Immunoglobulin turnover studies appear to be an additional means for the characterization of rheumatic diseases.

Entities:  

Mesh:

Substances:

Year:  1970        PMID: 5309797      PMCID: PMC322526          DOI: 10.1172/JCI106283

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  40 in total

1.  GAMMA-2, GAMMA-1A AND GAMMA-1M ANTINUCLEAR FACTORS IN HUMAN SERA.

Authors:  E V BARNETT; J J CONDEMI; J P LEDDY; J H VAUGHAN
Journal:  J Clin Invest       Date:  1964-06       Impact factor: 14.808

2.  FACTORS CONTROLLING SERUM GAMMA-GLOBULIN CONCENTRATION.

Authors:  J L FAHEY; A G ROBINSON
Journal:  J Exp Med       Date:  1963-11-01       Impact factor: 14.307

3.  The turnover and distribution of I-131-labeled myeloma and macroglobulin proteins.

Authors:  T G GABUZDA
Journal:  J Lab Clin Med       Date:  1962-01

4.  Human gamma globulin fractionation on anion exchange cellulose columns.

Authors:  J L FAHEY; A P HORBETT
Journal:  J Biol Chem       Date:  1959-10       Impact factor: 5.157

5.  The latex fixation test. I. Application to the serologic diagnosis of rheumatoid arthritis.

Authors:  C M PLOTZ; J M SINGER
Journal:  Am J Med       Date:  1956-12       Impact factor: 4.965

6.  The plasma disappearance time and catabolic half-life of I-131-labeled normal human gamma globulin in amyloidosis and inrheumatoid arthritis.

Authors:  J A MILLS; E CALKINS; A S COHEN
Journal:  J Clin Invest       Date:  1961-10       Impact factor: 14.808

7.  Immunoglobulins G, A, and M in systemic lupus erythematosus. Relationship to serum complement titer, latex titer, antinuclear antibody, and manifestations of clinical disease.

Authors:  R M Cass; E S Mongan; R F Jacox; J H Vaughan
Journal:  Ann Intern Med       Date:  1968-10       Impact factor: 25.391

8.  Accelerated breakdown of immunoglobulin G (IgG) in myotonic dystrophy: a hereditary error of immunoglobulin catabolism.

Authors:  R D Wochner; G Drews; W Strober; T A Waldmann
Journal:  J Clin Invest       Date:  1966-03       Impact factor: 14.808

9.  EVIDENCE FOR SPECIES' DIFFERENCES IN THE EFFECT OF SERUM GAMMA-GLOBULIN CONCENTRATION ON GAMMA-GLOBULIN CATABOLISM.

Authors:  S SELL
Journal:  J Exp Med       Date:  1964-11-01       Impact factor: 14.307

10.  Immunological studies concerning the nephritis of systemic lupus erythematosus.

Authors:  D Koffler; P H Schur; H G Kunkel
Journal:  J Exp Med       Date:  1967-10-01       Impact factor: 14.307

View more
  18 in total

1.  Mimotopic peptide immunotherapy for the treatment of multiple sclerosis, an inflammatory autoimmune disease.

Authors:  Emanuel Calenoff
Journal:  Am J Clin Exp Immunol       Date:  2013-10-16

2.  Metabolism of autologous and homologous IgG in rheumatoid arthritis.

Authors:  M A Catalano; E H Krick; D H De Heer; R M Nakamura; A N Theofilopoulos; J H Vaughan
Journal:  J Clin Invest       Date:  1977-08       Impact factor: 14.808

3.  Clinical and biochemical assessment of anti-inflammatory substances.

Authors:  P Franchimont
Journal:  Agents Actions       Date:  1976-02

Review 4.  Prolonged thoracic-duct drainage in rheumatoid arthritis and systemic lupus erythematosus.

Authors:  H E Paulus; H I Machleder; P J Clements; K Nyman; S Levine
Journal:  West J Med       Date:  1979-04

5.  Differences in serum IgG structure in health and rheumatoid disease. Circular dichroism studies.

Authors:  P M Johnson; J Watkins; P M Scopes; B M Tracey
Journal:  Ann Rheum Dis       Date:  1974-07       Impact factor: 19.103

6.  Catabolism of human serum IgG in health, rheumatoid arthritis, and active tuberculous disease. Possible influence of IgG structure.

Authors:  J Watkins; A J Swannell
Journal:  Ann Rheum Dis       Date:  1973-05       Impact factor: 19.103

7.  Increased frequency of B8/DR3 in scleroderma and association of the haplotype with impaired cellular immune response.

Authors:  C G Kallenberg; J M Van der Voort-Beelen; J D'Amaro; T H The
Journal:  Clin Exp Immunol       Date:  1981-03       Impact factor: 4.330

8.  The effect of azathioprine on gammaglobulin synthesis in man.

Authors:  J Levy; E V Barnett; N S MacDonald; J R Klinenberg; C M Pearson
Journal:  J Clin Invest       Date:  1972-09       Impact factor: 14.808

9.  Increased numbers of active B cells in the circulation of patients with rheumatoid arthritis.

Authors:  C F Corke; V Gul; H E Stierle; E C Huskisson; E J Holborow
Journal:  Rheumatol Int       Date:  1984       Impact factor: 2.631

10.  B cell activity in systemic lupus erythematosus: depressed in vivo humoral immune response to a primary antigen (haemocyanin) and increased in vitro spontaneous immunoglobulin synthesis.

Authors:  C G Kallenberg; P C Limburg; C Van Slochteren; F J Van der Woude; T H The
Journal:  Clin Exp Immunol       Date:  1983-08       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.